- Details
- Fred Saad joins Zachary Klaassen to discuss a subgroup analysis of the PEACE-3 trial, which evaluated enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer. Dr. Saad highlights how bone-protective agents (BPAs), made mandatory after high fracture rates were observed, significantly impact outcomes. Among 115 pre-mandate patients, those receiving BPAs gained 14 m...
|
- Details
- Umang Swami joins Alicia Morgans to discuss real-world bone health agent utilization in metastatic castration-resistant prostate cancer. Analyzing the Flatiron Health database of 14,000 mCRPC patients from 250 centers nationwide, Dr. Swami reveals a concerning trend: after increasing from 56% to 65% between 2013-2015, bone hardener utilization has declined to approximately 46% in recent years. Thi...
|
- Details
- Alicia Morgans is joined by Arnoud Templeton to discuss the REDUSE trial. This non-inferiority study compares denosumab administered every four weeks versus twelve weeks in patients with metastatic castration-resistant prostate cancer. After a median follow-up of 2.4 years, patients receiving less frequent dosing show lower rates of osteonecrosis of the jaw and tooth infections, with differences b...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Noel Clarke presents findings from the STAMPEDE trial regarding fracture risk and bone protection in prostate cancer patients. The presentation demonstrates that zoledronic acid reduces fracture incidence by about 50% in metastatic disease, and treatment intensification with abiraterone shows substantial fracture risk reduction, wh...
|
- Details
- Rashid Sayyid and Zach Klaassen review the 2024 NCCN prostate cancer guideline updates focusing on treatment-related bone loss in patients on androgen deprivation therapy (ADT). They emphasize the importance of addressing bone health due to increased fracture risk associated with ADT. The speakers outline a comprehensive approach to bone health management, including risk assessment using the FRAX...
|
- Details
- Rashid Sayyid and Zach Klaassen review the NCCN prostate cancer guideline updates regarding the prevention of symptomatic skeletal-related events in bone metastatic CRPC patients. They discuss the efficacy and safety profiles of denosumab and zoledronic acid, highlighting key clinical trials that have shaped current recommendations. The speakers emphasize the importance of considering dosing frequ...
|
- Details
- Urologist Neal Shore joins Alicia Morgans in a conversation on the multidisciplinary approach and successful incorporation of radium-223 dichloride (radium-223) into the treatment algorithm for men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. Drs. Shore and Morgans talk through the challenges care teams face when planning the administration of radiu...
|
- Details
- In this discussion, Nicholas James and Alicia Morgans discuss the relationship between alkaline phosphatase decline and overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases treated with radium-223 (Ra-223) in the global real-world REASSURE study. REASSURE is evaluating the long-term safety of Radium 223 in routine clinical practice in...
|
- Details
- Alicia Morgans speaks with Neal Shore about advancements in treating metastatic castration-resistant prostate cancer (mCRPC). They discuss the implications of the newly approved PSMA-RLT lutetium-617, a radiopharmaceutical, adding it to a list of existing therapies such as taxane therapy, PARP inhibitors, and immunotherapies like sipuleucel-T. Dr. Shore emphasizes that monotherapy is no longer acc...
|
- Details
- Tanya Dorff and Alicia Morgans discuss the importance of multidisciplinary care teams for patients with bone metastatic castration-resistant prostate cancer (mCRPC). The pair talk about the need for clear communication between physicians, radiation oncologists, and nuclear medicine physicians on the team, as well as the importance of the nursing and imaging staff. Dr. Dorff also stresses the impor...
|
